Crossmark

Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in Patients with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the UK

Published Online: 2022-05-11

Published Print: 2022-06

Authors

McCrimmon, Rory J. http://orcid.org/0000-0002-3957-1981
Palmer, Karen

Alsaleh, Abdul Jabbar Omar

Lew, Elisheva

Puttanna, Amar
Funding

Funding for this research was provided by:

Sanofi
License Information

Text and Data Mining valid from 2022-05-11

Version of Record valid from 2022-05-11
More Information

Article History

Received: 24 January 2022

Accepted: 20 April 2022

First Online: 11 May 2022

Document is current